Risk of severe COVID-19 in patients treated with IBD medications : a French nationwide study

© 2021 John Wiley & Sons Ltd..

BACKGROUND: Recently, the SECURE-IBD study, based on a physician-reported registry, suggested that thiopurines, either alone or combined with anti-TNF, may increase risk of severe COVID-19.

AIMS: To compare the risk of severe COVID-19 according to IBD medications in a large and unselected population.

METHODS: Using the French national health data system, the risks of hospitalisation and of death or mechanical ventilation for COVID-19 from 15 February 2020 to 31 August 2020 in IBD patients were compared according to IBD treatment (immunomodulators and biologics), using multivariable Cox models adjusted for socio-demographic characteristics, budesonide/corticosteroids and aminosalicylates use, and comorbidities.

RESULTS: Among 268 185 IBD patients, 600 were hospitalised for COVID-19 and 111 of them died or were mechanically ventilated (including 78 deaths). In multivariable analysis, the risk of hospitalisation for COVID-19 did not differ according to IBD treatment category, with adjusted Hazard Ratios (aHR, unexposed patients used as reference) of 0.94 (95%CI: 0.66-1.35) for immunomodulator monotherapy, 1.05 (0.80-1.38) for anti-TNF monotherapy, 0.80 (0.38-1.69) for anti-TNF combination therapy, 1.06 (0.55-2.05) for vedolizumab and 1.25 (0.64-2.43) for ustekinumab. Similarly, the risk of death or mechanical ventilation for COVID-19 did not differ according to IBD treatment.

CONCLUSIONS: Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID-19 infection.

Errataetall:

CommentIn: Aliment Pharmacol Ther. 2021 Jul;54(2):208-209. - PMID 34170535

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Alimentary pharmacology & therapeutics - Vol. 54, No. 2 (2021), p. 160-166

Language:

English

Contributors:

Meyer, Antoine
Semenzato, Laura
Zureik, Mahmoud
Weill, Alain
Carbonnel, Franck
Dray-Spira, Rosemary

Urls:

Volltext

Keywords:

*COVID-19
*Inflammatory Bowel Diseases
Humans
Immunologic Factors
Journal Article
SARS-CoV-2
Tumor Necrosis Factor Inhibitors

Notes:

Date Completed 30.06.2021

Date Revised 30.06.2021

published: Print-Electronic

CommentIn: Aliment Pharmacol Ther. 2021 Jul;54(2):208-209. - PMID 34170535

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1111/apt.16410

PMID:

34110040

PPN (Catalogue-ID):

NLM327738731